These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
426 related items for PubMed ID: 12750699
21. Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. Dhédin N, Prébet T, De Latour RP, Katsahian S, Kuentz M, Piard N, Réa D, Norol F, Jouet JP, Ribeil JA, Tabrizi R, Rio B, Lioure B, Tiberghien P, Bourhis JH, Sirvent A, Bordigoni P, Blaise D, Michallet M, Vernant JP. Bone Marrow Transplant; 2012 Dec; 47(12):1564-8. PubMed ID: 22609881 [Abstract] [Full Text] [Related]
23. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold? Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Horton C, Millar B, Shepherd V, Tait D, Saso R, Rowland A, Long S, Mehta J. Bone Marrow Transplant; 2000 Sep; 26(5):489-96. PubMed ID: 11019837 [Abstract] [Full Text] [Related]
34. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation. Dhédin N, Chamakhi I, Perreault C, Roy DC, Sauvageau G, Ducruet T, Busque L, Fish D, Bélanger R, Roy J. Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397 [Abstract] [Full Text] [Related]
35. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT. Urbano-Ispizua A, Solano C, Brunet S, de la Rubia J, Odriozola J, Zuazu J, Figuera A, Caballero D, Martínez C, García J, Sanz G, Torrabadella M, Alegre A, Pérez-Oteiza J, Jurado M, Oyonarte S, Sierra J, García-Conde J, Rozman C. Bone Marrow Transplant; 1998 Sep; 22(6):519-25. PubMed ID: 9758337 [Abstract] [Full Text] [Related]
36. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Lee SH, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K. Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073 [Abstract] [Full Text] [Related]
37. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients. Gonzalez-Vicent M, Perez A, Abad L, Sevilla J, Ramirez M, Diaz MA. J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238 [Abstract] [Full Text] [Related]
39. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R, Martin PJ, Flowers ME, Storek J, Georges G, Storb R, Torok-Storb B. Blood; 2001 Dec 01; 98(12):3221-7. PubMed ID: 11719357 [Abstract] [Full Text] [Related]
40. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei C, Latini P, Reisner Y, Martelli MF. N Engl J Med; 1998 Oct 22; 339(17):1186-93. PubMed ID: 9780338 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]